scispace - formally typeset
J

Jüri Reimand

Researcher at Ontario Institute for Cancer Research

Publications -  99
Citations -  12527

Jüri Reimand is an academic researcher from Ontario Institute for Cancer Research. The author has contributed to research in topics: Cancer & Biology. The author has an hindex of 36, co-authored 76 publications receiving 9751 citations. Previous affiliations of Jüri Reimand include University of Toronto & University of California, Santa Cruz.

Papers
More filters
Journal ArticleDOI

g:Profiler—a web server for functional interpretation of gene lists (2016 update)

TL;DR: The 2016 update of g:Profiler introduces several novel features, including transcription factor binding site predictions, Mendelian disease annotations, information about protein expression and complexes and gene mappings of human genetic polymorphisms.
Journal ArticleDOI

g:Profiler--a web-based toolset for functional profiling of gene lists from large-scale experiments.

TL;DR: G:Profiler has a simple, user-friendly web interface with powerful visualisation for capturing Gene Ontology, pathway, or transcription factor binding site enrichments down to individual gene levels.
Journal ArticleDOI

Pathway enrichment analysis and visualization of omics data using g:Profiler, GSEA, Cytoscape and EnrichmentMap

TL;DR: This protocol describes pathway enrichment analysis of gene lists from RNA-seq and other genomics experiments using g:Profiler, GSEA, Cytoscape and EnrichmentMap software, and describes innovative visualization techniques.
Journal ArticleDOI

Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups

Kristian W. Pajtler, +61 more
- 11 May 2015 - 
TL;DR: The molecular classification proposed herein outperforms the current histopathological classification and thus might serve as a basis for the next World Health Organization classification of CNS tumors.
Journal ArticleDOI

Subgroup-specific structural variation across 1,000 medulloblastoma genomes

Paul A. Northcott, +139 more
- 02 Aug 2012 - 
TL;DR: Somatic copy number aberrations (SCNAs) in 1,087 unique medulloblastomas are reported, including recurrent events targeting TGF-β signalling in Group 3, and NF-κB signalling in Groups 4, which suggest future avenues for rational, targeted therapy.